Whole Genome Sequencing [WGS] Reveals Novel, Clinically Relevant Biomarkers Missed by Standards of Care for Pts w/ Myelodysplastic Syndrome [MDS] [Jun 11, 2026] @AlexBataller et al. #EHA2026 EHA-4897 PF656 library.ehaweb.org/eha/2026/… #MDSsm #leusm #cagenome @UTMDAnderson @TempusAI

Looking forward to hear Dr. Omar Nadeem’s from @DanaFarber updating the ImmunoPRISM tec SMM study later this morning at #EHA26 #EHA2026 #mmsm @IrenemGhobrial

MajesTEC-9 at #EHA26 #EHA2026 #mmsm

Not a plateau in whole cohort, but do the authors have info about MRD -ve VS. ve? Probably there we can see a plateau. @RahulBanerjeeMD

👉👉👉Sending a huge shout out to .@MyelomaTeacher - thanks for her wonderful patient advocacy in our field! We appreciate you so much ! Keep up your great work ! #EHA26 #EHA2026 @EHA_Hematology @HealthTree | #mmsm #MPNSM #BPDCN | 🙏 @mtmdphd for bringing us together!

@szusmani presenting CEPHEUS TIE Final analysis #EHA26 #EHA2026 #mmsm

#mmsm #EHA26 MajesTEC-4 Amazing data ✅ ≥CR was achieved in nearly 100% of patients across all 3 cohorts (100%, 96.9%, and 96.7%), up from roughly 41–60% post-ASCT ✅ Median PFS was not reached in any cohort. Estimated 18- and 24-month PFS rates were 94–97% Only 3 progression events across all 94 patients 👏 ✅ Grade 3/4 infections were lowest in the Tec Q4W monotherapy cohort (27%) vs. ~35–38% in the combination arms Beginning of an era of “no Lenalidomide maintenance and time limited BCMA maintenance Teclistimab continues to be impressive addition to the myeloma treatments

Dr. Niels van de Donk updating MajesTEC-4 at #EHA26 #EHA2026 #mmsm

Dr. Cyril’s Touzeau updating MajesTEC-9 at #EHA26 #EHA2026 #mmsm

🚨 MonumenTAL-3 #EHA2026 Talquetamab moves earlier in RRMM Phase 3 MonumenTAL3 met its primary endpoint, showing significant PFS improvement versus DPd in patients with relapsed/refractory multiple myeloma after ≥1 prior line #mmsm

CONGRESS | #EHA2026 | POSTER Naveen Pemmaraju shares real-world findings from a retrospective cohort study evaluating the treatment patterns and outcomes of pacritinib in patients with #myelofibrosis stratified by platelet (PLT) counts (N = 168). Category 1 reduction in spleen size was observed in 62% and 71% of patients with PLT <50x109/L and ≥50x109/L, respectively. SLR≥25 was achieved by 82% and 83% of patients in the PLT <50x109/L and ≥50x109/L groups, while SLR≥50 was achieved by 41% and 25%, respectively. Median hemoglobin increased by 0.6 g/dL and 0.8 g/dL by Day 180 in patients with PLT <50x109/L and ≥50x109/L, respectively. Both groups showed a reduction in MF-related symptoms through Day 180. The findings highlight the potential of pacritinib in treating patients with MF with and without severe thrombocytopenia. Follow our live feed for more updates: loom.ly/N2uNnTk Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. a full list of supporters can be found on our website. #MPN #MPNsm #MedicalCongress @doctorpemm @UTMDAnderson

#EHA2026 matching pink! GPRC5D bsAbs took the limelight today, but looking forward to @SusanBal9 teaching us about GPRC5D CAR-T tomorrow!

#EHA2026 not a plateau, but what amazing results all the same! @szusmani presenting updated CEPHEUS data. 6 years out for some patients, median OS *still* not reached with D-VRd despite no transplant. Great to see long-term quad data emerging!

CONGRESS | #EHA2026 | PRESENTATION Cyrille Touzeau presents results from the phase III MajesTEC-9 study evaluating teclistamab monotherapy versus pomalidomide, bortezomib, and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd) in patients with RRMM. After a median follow-up of 17.3 months, median PFS was not reached with teclistamab versus 8.2 months with PVd/Kd (HR, 0.29; p < 0.0001). ORR was higher with teclistamab versus PVd/Kd (OR, 4.62; p < 0.0001). OS also favored teclistamab (HR, 0.60; p = 0.002). Infection rates were higher with teclistamab, including grade 5 infections (5.5% vs 2.8% with PVd/Kd). Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @CHUnantes

#EHA2026 #EHA26 #mdssm #poster_presentation #TP53-Mutated MDS: The CCR5 Axis as a Driver of T-Cell Exhaustion #TP53-mutated MDS exhibits a distinct exhausted T-cell phenotype with increased immune checkpoint expression. 🔹 Single-cell analyses identified activation of the CCR5 signaling axis as a key driver of T-cell dysfunction and immune escape.

@EHA_Hematology 2026: Day 4 Preview Explore more insights and data from #EHA2026 👉 clin.larvol.com/conference/a… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #EHA26 #YoungEHA #HemaSphere #EHA #Hematology #Leukemia #Lymphoma #MultipleMyeloma #BloodCancer #HemeOnc #MMSM #LEUSM #LYMSM | @smbenlazar | @calliecoombsmd | @RahulBanerjeeMD | @HadidiSamer | @DrRaulCordoba

#EHA2026 and congrats #cyrilletouzeau and the whole MajesTEC-9 team for such excellent results! Tec monotherapy joins our growing landscape of excellent treatment options as early as first relapse 👏

🙌 Delighted to be a part of our rapidly growing international MPN research community ! A wonderful, collegial group! @doctorpemm @Vikas_Gupta_1 @Barbara_MoraMD @sk_tantravahi | #MPNSM

#CMLsm #EHA2026 #PrecisionMedicine